

Attorney Docket No. See Attached Schedule A

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: See Attached Schedule Confirmation No.:
A.

Serial No.: See Attached Schedule Group Art Unit:
A

Filed: See Attached Schedule Examiner:
A

FOR: **SEE ATTACHED SCHEDULE A**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REVOCATION AND NEW POWER BY ASSIGNEE AND STATEMENT UNDER 37 C.F.R. §3.73(b)

The Assignee of less than the entire right, title, and interest (the extent (by percentage) of its ownership interest is 50) in the above-identified application hereby revokes all previously granted powers and grants the registered practitioners of Cooley LLP included in the Customer Number provided below power to act, prosecute, and transact all business in the U.S. Patent and Trademark Office in connection with this application, any applications claiming priority to this application, and any patents issuing therefrom.

The assignee certifies that to the best of its knowledge and belief it is an owner of less than the entire right, title, and interest (the extent (by percentage) of its ownership interest is 50) in and to the above-identified application as evidenced by:


- ☐ An assignment document, a copy of which is enclosed herewith and is being recorded with the U.S. Patent and Trademark Office concurrently herewith;
- ☒ An assignment previously recorded in the U.S. Patent and Trademark Office at Reel See Attached Schedule A, Frame See Attached Schedule A.

Please direct all telephone calls and correspondence to:

CUSTOMER NUMBER: **58249**

COOLEY LLP
ATTN: Patent Group
777 6th Street NW, Suite 1100
Washington, DC 20001
Tel: (206) 452-8700
Fax: (202) 842-7899

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

Date: April 24, 2012 Signature: 
Name: BARRY MCGURL
Title: DIRECTOR, INTELLECTUAL PROPERTY
Company: Tekmira Pharmaceuticals Corporation

SCHEDULE A
to Revocation and Power of Attorney with Change of Correspondence Address
and Statement Under 37 CFR 3.73(b)
for Tekmira Pharmaceuticals Corporation and The University of British Columbia

Patent No.	Issue Date	First Named Inventor	Attorney Docket No.	Title of Invention	Reel/Frame
5,705,385	1/6/1998	BALLY, Marcel	TEKM-025/01US 311118-2253	LIPID-NUCLEIC ACID PARTICLES PREPARED VIA A HYDROPHOBIC LIPID-NUCLEIC ACID COMPLEX INTERMEDIATE AND USE FOR GENE TRANSFER	019287/0631
5,976,567	11/2/1999	WHEELER, Jeffery	TEKM-025/02US 311118-2256	LIPID-NUCLEIC ACID PARTICLES PREPARED VIA A HYDROPHOBIC LIPID-NUCLEIC ACID COMPLEX INTERMEDIATE AND USE FOR GENE TRANSFER	019287/0631
5,981,501	11/9/1999	WHEELER, Jeffery	TEKM-041/00US 311118-2239	METHODS FOR ENCAPSULATING PLASMIDS IN LIPID BILAYERS	019287/0631
6,534,484	3/18/2003	WHEELER, Jeffery	TEKM-041/01US 311118-2229	METHODS FOR ENCAPSULATING PLASMIDS IN LIPID BILAYERS	019287/0631
6,586,410	7/1/2003	WHEELER, Jeffery	TEKM-025/04US 311118-2259	LIPID-NUCLEIC ACID PARTICLES PREPARED VIA A HYDROPHOBIC LIPID-NUCLEIC ACID COMPLEX INTERMEDIATE AND USE FOR GENE TRANSFER	019287/0631
6,815,432	11/9/2004	WHEELER, Jeffery	TEKM-041/02US 311118-2221	METHODS FOR ENCAPSULATING PLASMIDS IN LIPID BILAYERS	019287/0631
6,858,224	2/22/2005	WHEELER, Jeffery	TEKM-025/05US 311118-2009	METHOD OF PREVENTING AGGREGATION OF A LIPID-NUCLEIC ACID COMPLEX	019287/0631
7,422,902	9/9/2008	WHEELER, Jeffery	TEKM-025/03US 311118-2257	LIPID-NUCLEIC ACID PARTICLES PREPARED VIA A HYDROPHOBIC LIPID-NUCLEIC ACID COMPLEX INTERMEDIATE AND USE FOR GENE TRANSFER	019287/0631